Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Late-Breaking KidneyIntelX Evidence Released at 83rd American Diabetes Association Scientific Sessions

Published

on

12 Months KidneyIntelX™ in vitro prognostic testing continued to demonstrate clinical actions that lead to improvement in both diabetes (A1C reductions) and kidney health (eGFR slope improvement) in patients with Type 2 Diabetes and Chronic Kidney Disease

LONDON and SALT LAKE CITY, July 07, 2023 (GLOBE NEWSWIRE) — Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced late-breaking new clinical data demonstrating that KidneyIntelX in vitro prognostic use was associated with post-test actions that led to sustained improvements in both type 2 diabetes and chronic kidney disease health through 12 months. The results are from the evaluation of 2,317 patients being followed in a large real-world evidence (RWE) study in New York City. The twelve-month outcome data were presented at the American Diabetes Association (ADA) 83rd Scientific Sessions held June 23-26, 2023, in San Diego, California.

There are approximately 14 million adults with diabetic kidney disease in the U.S. today1, and that number could more than double by the year 20602 due to rising trends in obesity and diabetes. KidneyIntelX is designed for use in patients with type 2 diabetes and stages 1-3 of kidney disease (early-stage diabetic kidney disease, DKD) to assess which patients are at low, intermediate, or high risk for a rapid progressive decline in their kidney function.

Type 2 Diabetes Improvements Evidenced by Hemoglobin A1c in Higher Risk Groups:

In patients classified as high risk, median A1C levels improved by 0.7%, a decrease from 8.2% (pre-test) to 7.5 (post-test) at one year (p< 0.001); median HbA1c decreased from 7.5% to 7.3% for patients in the intermediate risk group (p=0.001), and median A1C decreased from 7.1% to 7.0% in the low risk patients. (p=0.9).

These results support that the previously published improvement in A1C levels observed at six months pre and post KidneyIntelX testing, has been sustained for the full year, especially in the higher-risk patients.

Kidney Disease Improvement or Stability Demonstrated by Median eGFR Slope Improvement Across all Risk Groups

GFR slope is widely accepted as a clinical measure to determine the progression of chronic kidney disease (CKD). In patients classified as high risk by KidneyIntelX, median eGFR slope improved from -7.1 (pre-test) to 4.5ml/min/1.73m2 (post-test) at one year (p=0.01), indicating a slowed progression of their disease. For patients with an intermediate risk score, median eGFR slope was stable at -1.5 (pre vs. post-test) to -1.4ml/min/1.73m2 at one year (p=0.6) while patients classified as low risk, the median eGFR slope improved from -1.9 (pre-test) to -0.28 ml/min/1.73 m2/year (p<0.01), further highlighting a need for broad engagement at both ends of the risk spectrum.

This data builds upon the RWE 6-month interim results published in the Journal of Primary Care and Community Health (November 2022) which demonstrated a reduction in the amount of urinary (albumin) protein in the low and intermediate KidneyIntelX risk groups.

The authors concluded that the use and deployment of KidneyIntelX to risk stratify patients with early-stage diabetic kidney disease was associated with escalation in various actions taken to optimize cardio-metabolic-kidney health, including guideline-based pharmacy management and specialist consultation. Furthermore, glycemic control and kidney health improved post-KidneyIntelX testing, with the largest improvements observed in those scored as high-risk.

Importantly this data demonstrates that implementation of KidneyIntelX in patient care leads to improved clinician and patient engagement directed to slowing the progression of diabetic kidney disease and associated cardiovascular complications.

In addition, during the ADA meetings, the Company presented validation data from a new IVD assay developed utilizing the KidneyIntelX platform. The risk score calculation was updated to incorporate the new race-free eGFR calculation, the availability of contemporary patient cohorts reflecting recent changes in care for diabetic kidney disease, and simplification of test inputs to enhance clinical adoption in the primary care setting.

The updated version of KidneyIntelX utilizes the same three biomarkers, and three clinical features. It was validated in an external cohort with overall excellent performance characteristics which included diverse subgroups of the intended use population.

Commenting on the data releases at the American Diabetes Association 83rd Scientific Sessions, Dr. Michael Donovan, Chief Medical Officer at Renalytix adds, “We are at an important inflection point in the overall understanding and management of kidney disease progression in the type 2 diabetic patient population. Precision based tools such as the KidneyIntelX assay provide a patient-level biological assessment of (DKD) disease potential for which population-based algorithms based on standard clinical variables will never be able to achieve.”

About Chronic Kidney Disease

Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. The Centers for Disease Control and Prevention (CDC) estimates that 15% of US adults, more than 38 million people, currently have chronic kidney disease (CKD). Diabetes is the leading cause of kidney failure, accounting for 44% of new cases. Further, the CDC reports that 9 out of 10 adults with CKD do not know they have it and one out of two people with very low kidney function who are not on dialysis do not know they have CKD.1 Kidney disease is referred to as a “silent killer” because it often has no symptoms and can go undetected until a very advanced stage. Each year, kidney disease kills more people than breast and prostate cancer. Every day, 13 patients in the United States die while waiting for a kidney transplant.

About Type 2 Diabetes

More than 37 million Americans have diabetes (about 1 in 10), and approximately 90-95% of them have type 2 diabetes. Type 2 diabetes most often develops in people over age 45, but more and more children, teens, and young adults are also developing the disease2. Type 2 diabetes symptoms often develop over several years and approximately 23% of adults with Type 2 Diabetes are undiagnosed3. Type 2 diabetes affects many major organs, including the heart, blood vessels, nerves, eyes and kidneys. Diabetic Kidney Disease develops in 30-50% of Type 2 diabetes patients4.

About Renalytix

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.

About KidneyIntelX™

KidneyIntelX™ is a laboratory developed test demonstrated to be a reliable, bioprognostic™ methodology that yields a simple-to-understand, custom risk score, enabling prediction of which adult patients with T2D and early CKD (stages 1-3) are at low, intermediate or high risk for rapidly progressive decline in kidney function. By combining information from KidneyIntelX with newer cardio- and reno-protective therapies, doctors will have more information in determining which patients are at higher versus lower risk for rapid disease progression and may be able to more appropriately target resources and guideline-recommended treatments to advance kidney health. KidneyIntelX is supported by a growing body of clinical, utility and health economic studies (including a validation study of two large cohorts) and has demonstrated a 72% improvement in predicting those patients who are at high risk for rapid progressive decline in kidney function versus the current standard of care (eGFR and UACR). To learn more about KidneyIntelX and review the evidence, visit www.kidneyintelx.com.

Sources

https://www.theisn.org/blog/2020/11/27/more-than-850-million-worldwide-have-some-form-of-kidney-disease-help-raise-awareness/
2 https://www.cdc.gov/diabetes/basics/type2.html
3 https://www.cdc.gov/diabetes/data/statistics-report/index.html
4 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5297507/

Forward Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Examples of these forward-looking statements include statements concerning: the potential benefits, including economic savings, of KidneyIntelX, the impact KidneyIntelX can have on patients’ care management, the commercial prospects of KidneyIntelX, including whether and to what extent KidneyIntelX will be successfully adopted by physicians and distributed and marketed, our expectations regarding reimbursement decisions and the ability of KidneyIntelX and other potential tests developed using the KidneyIntelX platform to curtail costs of chronic and end-stage kidney disease, optimize care delivery, address systemic inequalities and improve patient outcomes. Words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “seeks,” and similar expressions are intended to identify forward-looking statements. We may not actually achieve the plans and objectives disclosed in the forward-looking statements, and you should not place undue reliance on our forward-looking statements. Any forward-looking statements are based on management’s current views and assumptions and involve risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. These risks and uncertainties include, among others: that KidneyIntelX is based on novel artificial intelligence technologies that are rapidly evolving and potential acceptance, utility and clinical practice remains uncertain; we have only recently commercially launched KidneyIntelX; and risks relating to the impact on our business of the COVID-19 pandemic or similar public health crises. These and other risks are described more fully in our filings with the Securities and Exchange Commission (SEC), including the “Risk Factors” section of our annual report on Form 20-F filed with the SEC on October 31, 2022, and other filings we make with the SEC from time to time. All information in this press release is as of the date of the release, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.

Media Contacts:
United States:
Karla Gonye
Renalytix
617-590-5731

[email protected]

David Schull or Ignacio Guerrero-Ros, Ph.D.
Russo Partners
858-717-2310
646-942-5604
[email protected]
[email protected]

Outside of the United States:
Walbrook PR Limited
Paul McManus / Lianne Applegarth / Alice Woodings

Tel: 020 7933 8780 or [email protected]
Mob: 07980 541 893 / 07584 391 303 / 07407 804 654

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

ICIS announces the 16th Asian Base Oils and Lubricants Conference in Singapore

Published

on

icis-announces-the-16th-asian-base-oils-and-lubricants-conference-in-singapore

LONDON, May 20, 2024 /PRNewswire/ — ICIS, a global source of commodity intelligence, has announced the 16th Asian Base Oils and Lubricants Conference will take place in Singapore, 27-28 June 2024. The event offers a platform for senior executives to connect with peers, potential clients and industry leaders, offering insight into the latest trends, innovation and best practices within the industry.

Dr Sarawut Kaewtathip, Director General – Department of Mineral Fuels from the Ministry of Energy, Thailand will present a keynote delving into the Thai fuels and lubricants market. He will offer insight into growth opportunities within the automotive sector following COVID-19 and explain how the base oils and lubricants industry can support future developments.
The conference will also include exclusive market data from Michael Connolly, Principal Analyst, Refining at ICIS, who comments: “While Asian prices have been less impacted by global events than in other regions, it has still been affected, which is highlighted by further Group I closures in the region. This conference provides a vital platform to exchange knowledge and come together to learn collectively about the latest industry developments, whilst finding out how to best navigate uncertainty in the coming years.”
Delegates will also benefit from insight by Yan Chuang Zhao, Supervising Engineer of R&D Center at Great Wall Motors, who will be discussing ‘The wider Electric Vehicle picture in Asia’ and Charlotte Kehoe, AsPac Technology Director at bp Castrol who, who adds to the extensive line-up of speakers that conference attendees have come accustomed to. Charlotte will be looking to provide further insight into opportunities with data centres and immersion coolants across the region.
To find out more about the 16th ICIS Asian Base Oils and Lubricants Conference, or register for the event, please visit: https://events.icis.com/asian-base-oils/
About ICIS
ICIS – Independent Commodity Intelligence Services – helps businesses through seamlessly delivering data and analytics, across the chemical, and energy markets. A trusted source and benchmark for price information and insight across key commodities markets worldwide. Our independent, transparent market intelligence informs thousands of quality decisions every day, taking the pressure out of negotiations and giving customers space for more innovative thinking, through published datasets including price assessments, price forecasts, supply and demand fundamentals and more.
Over 150 years of shaping the world by connecting markets to optimise the world’s valuable resources. With a global team of more than 600 experts, ICIS has employees based in London, New York, Houston, Karlsruhe, Milan, Mumbai, Singapore, Guangzhou, Beijing, Shanghai, Dubai, Sao Paulo, Seoul, Tokyo and Perth.
ICIS is part of RELX, a FTSE15 company with a market cap of $78.2bn and an employee base of over 30,000 experts across 40 countries.
About RELX
RELX is a global provider of information and analytics for professional and business customers across industries. The Group serves customers in more than 180 countries and has offices in about 40 countries. It employs approximately 30,000 people of whom almost half are in North America. RELX PLC is a London listed holding company which owns 52.9% of RELX Group. RELX NV is an Amsterdam listed holding company which owns 47.1% of RELX Group. The shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX and RENX. Total market capitalisation is approximately £64.7bn |  €75.5bn |  $81.9bn.
Logo – https://mma.prnewswire.com/media/619935/4713254/ICIS_Logo.jpg

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/icis-announces-the-16th-asian-base-oils-and-lubricants-conference-in-singapore-302149492.html

Continue Reading

Artificial Intelligence

Subang Jaya Medical Centre Applauded by Frost & Sullivan as the Best Hospital Company of the Year in Malaysia for the fourth consecutive year

Published

on

subang-jaya-medical-centre-applauded-by-frost-&-sullivan-as-the-best-hospital-company-of-the-year-in-malaysia-for-the-fourth-consecutive-year

SJMC’s significant efforts in alleviating nursing shortages, enhancing workflows and its strong market-leading position, both locally and globally resulted in high patient retention and strong referrals.
SAN ANTONIO, May 20, 2024 /PRNewswire/ — Frost & Sullivan recently analyzed the hospital industry and noted that operational inefficiencies, workflow interruptions and shortage of skilled healthcare professionals are some key challenges faced by the healthcare industry. Based on its findings, Subang Jaya Medical Centre (SJMC) is recognized with the 2024 Malaysian Best Hospital Company of the Year Award for the fourth consecutive year in the hospitals industry, making it the first to be recognized continuously with this prestigious accolades

The company is a private hospital with 443 licensed beds and over 150 outpatient clinics. It handles approximately 50,000 admissions and 550,000 outpatient visits annually. With a workforce of around 1,600 healthcare professionals, SJMC offers services across more than 260 medical specialties encompassing diverse therapeutic areas such as oncology, cardiology, orthopedics, digestive health as well as women and children health.
Bhaskar Vittal, industry principal at Frost & Sullivan, observed, “SJMC provides comprehensive and integrated care, implementing practices aimed at achieving the best possible outcomes for patients. A typical cancer patient journey at SJMC starts with awareness-building and screening programs, continuing with diagnosis, treatment, and aftercare, which includes support groups, educators, and counselors—all key elements in cancer care management.
SJMC is a finalist flagship medical tourism hospital selected by the Malaysian Healthcare Travel Council (MHTC) which is fully endorsed by the Malaysian Ministry of Health. It has achieved several accreditations including the Joint Commission International (JCI) Accreditation and aims at providing patients a seamless transition throughout their health journey in Malaysia. Patient onboarding follows a process-oriented approach from the inquiry level, where patients receive detailed information on available services, specialist doctors, and treatment availability.
SJMC has achieved international branding and recognition for its Cancer & Radiosurgery Centre (CRC), known for its person-centered care approach. Moreover, the hospital has been credited by the Australian Council on Healthcare Standards International (ACHSI) as the first Center of Excellence (CoE) for oncology services in Asia-Pacific, marking a milestone achievement. SJMC continuously improves patient treatment options, expands day care surgical offerings, and prioritizes safety, faster recovery, and lower costs in line with industry trends to achieve medical excellence.
The hospital’s Genetic Wellness, a first-of-its-kind clinical-grade genetics testing program, provides more than 1,000 insights into patients’ health conditions based on their unique genetic blueprint. The test provides individualized information on a wide range of conditions, including chronic, infectious, and metabolic diseases, allergies, and drug responses, allowing individuals to make informed choices for their overall wellbeing.
SJMC became the first hospital in Malaysia to introduce a remote patient monitoring system, SeniorConnect, that is tailored to the unique needs of senior patients and is particularly beneficial in urban settings, where it is common for working adults to face challenges in caring for their elderly relatives. It is also the first hospital in Malaysia to perform day care robotic-assisted total knee replacement and total hip replacement procedures using the Mako SmartRobotics system. It also focuses on preventive and precision healthcare—key trends in the global healthcare industry.
Its continuous glucose monitoring (CGM) technology allows diabetes patients to continuously monitor and control their blood glucose. SJMC also successfully conducted a clinical improvement project, titled “Reducing Early Morning In-Patient Hypoglycemia Incidence among In-Patient Adults with Type 2 Diabetes Mellitus in non-Critical Care Wards,” which found that patients adhering to the recommended snack regimen experienced zero hypoglycemic incidents. SJMC aims to enhance diabetes wellness with its multidisciplinary approach through revolutionary technology and in-depth research.
SJMC’s artificial intelligence (AI)-powered Radixact X9 with Synchrony synchronizes the movement of radiation beams with the tumor’s motion, allowing seamless and continuous radiation delivery during the patient’s natural breathing patterns. This technology enables delivering accurate radiation dosage while minimizing exposure to healthy tissues.
“SJMC’s digital technologies and equipment enhance the patient journey, improve clinical outcomes, and provide the healthcare workforce with the best tools to achieve their medical excellence goals,” added Vittal.
Bryan Lin, Chief Executive Officer of SJMC expressed his gratitude for receiving this prestigious recognition for the fourth time, saying, “We’re honored to be recognized for the exceptional care our dedicated staff provides. Their unwavering commitment and teamwork are what truly make a difference for our patients. We’ll continue to pursue excellence and deliver world-class healthcare.”
“In today’s healthcare landscape, strengthening the healthcare workforce, enhancing workflows, and solidifying our market-leading position are paramount. We’re committed to achieving these goals by empowering our staff through training which improves the quality of patient care and equipping them with tools that enhance decision-making while encouraging them to embrace and learn in this digital healthcare era,” he adds.
With its excellent financial performance, seamless customer experiences, and strong overall performance, Subang Jaya Medical Centre’s unwavering dedication to exceptional healthcare is again recognized on the international stage, with their fourth consecutive award win.
Each year, Frost & Sullivan presents a Company of the Year award to the organization that demonstrates excellence in terms of growth strategy and implementation in its field. The award recognizes a high degree of innovation with products and technologies, and the resulting leadership in terms of customer value and market penetration.
Frost & Sullivan Best Practices awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.
About Frost & SullivanFor six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.
Contact:Tarini SinghP: +91-9953764546E:[email protected]
About SJMC
Subang Jaya Medical Centre (SJMC)
SJMC has an impeccable reputation as one of Malaysia’s most trusted private medical centres best known for its clinical outcomes. The hospital is an award-winning 443-bed multi-disciplinary tertiary hospital of CAH Medical Centres (previously known as Ramsay Sime Darby Health Care Group), providing comprehensive and complex care in all specialties.
It is one of the few internationally accredited Joint Commission International (JCI) hospitals in Malaysia and Malaysian Society for Quality in Health (MSQH) accredited. SJMC’s laboratory is also an internationally recognized MS ISO 15189 accredited since 2009. In 2023, SJMC Oncology (Cancer) Services is certified by Australian Council of Healthcare Standards (ACHS) International as a Centre of Excellence, making it the first in Asia-Pacific.
SJMC is recognized as a finalist for the Flagship Medical Tourism Hospital Programme 2023 – 2025 by Malaysia Healthcare Travel Council (MHTC) to establish Malaysia as a globally renowned icon for healthcare travel, delivering exceptional end-to-end patient experiences anchored on medical excellence, service excellence, and international branding. It receives both local patients across Malaysia and international patients across the Asia Pacific with over 47,000 admissions and almost half a million outpatient visits annually.
For more information, contact:Celia TanP: +60 17 930 8200E: [email protected] 
Nur Yee Jie MinP: +012 355 1885E: [email protected] 
Photo – https://mma.prnewswire.com/media/2415752/SJMC_Award.jpg

View original content:https://www.prnewswire.co.uk/news-releases/subang-jaya-medical-centre-applauded-by-frost–sullivan-as-the-best-hospital-company-of-the-year-in-malaysia-for-the-fourth-consecutive-year-302148854.html

Continue Reading

Artificial Intelligence

More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024

Published

on

more-than-$9-million-awarded-to-high-school-scientists-and-engineers-at-the-regeneron-international-science-and-engineering-fair-2024

Grace Sun, 16, receives $75,000 Top Award for a new kind of organic electrochemical transistor at the world’s largest pre-college science, technology, engineering and math (STEM) competition.
TARRYTOWN, N.Y. and WASHINGTON, May 17, 2024 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) announced that Grace Sun, 16, of Lexington, Kentucky, won the $75,000 top award, the George D. Yancopoulos Innovator Award, named in honor of the pioneering drug researcher and Regeneron co-Founder, Board co-Chair, President and Chief Scientific Officer, in the 2024 Regeneron International Science and Engineering Fair (Regeneron ISEF), the world’s largest pre-college science and engineering competition. Other top prizes went to projects in second-order cone programming, microplastics filtration and multi-sensory therapy for dementia.

The top winners were honored during two award ceremonies: the Special Awards on May 16 and the Grand Awards Ceremony on the morning of May 17. In total, over $9 million USD was awarded to the finalists based on their projects’ creativity, innovation and depth of scientific inquiry. The competition featured nearly 2,000 young scientists representing 49 U.S. states and nearly 70 countries, regions and territories across the world.
Grace Sun, 16, of Lexington, Kentucky, won first place and received the $75,000 George D. Yancopoulos Innovator Award for her research on building a better organic electrochemical transistor that she hopes will be used to develop new electronic devices that could help detect and treat serious illnesses like diabetes, epilepsy and organ failure. To overcome the problems that have previously prevented such devices from working effectively inside the body, Grace developed a new way of chemically treating their organic components, which greatly improved their laboratory performance.
Michelle Wei, 17, of San Jose, California, received one of two Regeneron Young Scientist Awards of $50,000 for her research to improve the speed and efficiency of a type of software that is useful in many fields such as machine learning, transportation and financial systems. Michelle’s new approach involved determining a quick approximate solution to the second-order cone programming problem, then splitting the initial cone into smaller cones, which enabled her new algorithm to greatly outperform previous approaches.
Krish Pai, 17, of Del Mar, California, received the second Regeneron Young Scientist Award of $50,000 for his machine-learning research to identify microbial genetic sequences that can be modified to biodegrade plastic. His new software, called Microby, scans databases of microorganisms and determines which ones can be changed genetically to biodegrade plastics. In tests, he identified two microorganisms that can be genetically modified to degrade plastic at a cost he believes would be ten times less than traditional recycling.
 “Congratulations to the Regeneron International Science and Engineering Fair 2024 winners,” said Maya Ajmera, President and CEO, Society for Science and Executive Publisher, Science News. “I’m truly inspired by the ingenuity and determination shown by these remarkable students. Coming from around the world with diverse backgrounds and academic disciplines, these students have shown that it is possible to come together in unity to tackle some of the toughest challenges facing our world today, and I could not be prouder.”
Regeneron ISEF provides a global stage for the world’s best and brightest young scientists and engineers. Through this competition, Regeneron and the Society are fostering the next generation of STEM leaders who are pioneering solutions to improve our world. Since 2020, Regeneron has provided STEM experiences to approximately 2.4 million students, on track to meet its goal of 2.5 million by 2025.
“The talent, intelligence and potential of this year’s Regeneron ISEF finalists is truly inspiring, and I congratulate each on their remarkable achievements,” said George D. Yancopoulos, M.D., Ph.D., co-Founder, Board co-Chair, President and Chief Scientific Officer of Regeneron. “Science competitions like ISEF were pivotal in shaping my own career and fueling my passion to fight back against disease. I look forward to seeing these students continue to push the boundaries of science and technology to create positive and sustainable change for all humanity.”
Other top honors from the competition include:
Justin Huang and Victoria Ou, both 17, of Woodlands, Texas, received the Gordon E. Moore Award for Positive Outcomes for Future Generations of $50,000 for their new prototype filtration system that uses ultrasonic waves to remove microscopic plastic particles from water. In lab tests, the acoustic force from the high-frequency sound waves removed between 84% and 94% of the suspended microplastic particles in a single pass. The students are now working to scale up and fine-tune their experimental system.
Ingrid Wai Hin Chan, 17, of Hong Kong, China received the Craig R. Barrett Award for Innovation of $10,000 for her research on using a multi-sensory therapy for dementia patients. Her mixed therapy app would allow patients to practice physical and cognitive skills through a personalized, immersive environment using virtual reality headsets. Ingrid conducted an eight-week study with six people living with dementia and found that the cognitive function of patients who used her prototype improved in several areas. She believes her app could serve as a viable option for dementia patients with limited access to in-person professional therapy.
Tanishka Balaji Aglave, 15, of Valrico, Florida, received the H. Robert Horvitz Prize for Fundamental Research of $10,000 for her investigation into a natural alternative treatment against citrus greening, a disease that threatens citrus farming in many parts of the world and is currently only treated with antibiotics. Tanishka injected the trunks of infected trees with an extract from the curry leaf tree, and found through tests that this potential method could effectively and sustainably manage citrus greening disease.
Maddux Alexander Springer, 18, of Honolulu, Hawaii, received the Peggy Scripps Award for Science Communication of $10,000 for his research into fibropapillomatosis (FP), a disease that is the primary cause of death in green sea turtles. Some turtles he studied in Kaneohe Bay, Hawaii, were stricken with a disease that causes internal and external tumors that inhibit their everyday lives. After analyzing the turtles’ diet of green algae, Maddux concluded that this disease, wastewater, invasive algae and the amino acid arginine all pose a grave risk to these endangered sea creatures.
Ria Kamat, 17, of Hackensack, New Jersey; Anna Oliva, 17, of Houston, TX; and Shuhan Luo, 18, of Worcester, MA, received the Dudley R. Herschbach SIYSS Award, which provides finalists an all-expense paid trip to attend the Stockholm International Youth Science Seminar during Nobel Week in Stockholm, Sweden.
Jack Shannon, 18, of Clane, Kildare, Ireland, and Nikhil Vemuri, 17, of Cary, North Carolina, received the EU Contest for Young Scientists Award. Their projects will represent Regeneron ISEF at the EU Contest for Young Scientists to be held this September in Katowice, Poland.
For more information about the top winners and access to visual assets visit:  https://www.societyforscience.org/isef-2024-media-kit.
The full list of Special Award ISEF 2024 Finalists can be found at https://www.societyforscience.org/press-release/regeneron-isef-2024-special-awards-winners.
In addition to the Top Award winners, more than 450 finalists received awards and prizes for their innovative research, including “First Award” winners, who each received a $5,000 prize.
The following lists the First Award winners for each of the 22 categories, from which the Top Awards were chosen:
Animal Sciences, sponsored by Society for ScienceMaddux Alexander Springer, Honolulu, Hawaii
Behavioral and Social Sciences, sponsored by Society for ScienceAndrew Y. Liang, San Jose, California
Biochemistry, sponsored by RegeneronAmy Hong Xiao, Garden City, New York
Biomedical and Health Sciences, sponsored by RegeneronRia Kamat, Hackensack, New Jersey; Kevin Xuan Lei, Shanghai, China
Biomedical Engineering, sponsored by Alfred E. Mann CharitiesAyush Garg, Dublin, California; Divij Motwani, Palo Alto, California; Akash Ashish Pai, Portland, Oregon
Cellular and Molecular Biology, sponsored by RegeneronLara and Maya Sarah Hammoud, Beverly Hills, Michigan
Chemistry, sponsored by Society for ScienceAkilan Sankaran, Albuquerque, New Mexico; Arjun Suresh Malpani and Siddharth Daniel D’costa, Portland, Oregon
Computational Biology and Bioinformatics, sponsored by RegeneronKun-Hyung Roh, Bronx, New York
Earth and Environmental Sciences, sponsored by Google.orgNikhil Vemuri, Durham, North Carolina; Justin Yizhou Huang and Victoria Ou, The Woodlands, Texas
Embedded Systems, sponsored by HPChloe Rae and Sophie Rose Filion, Welland, Ontario, Canada
Energy: Sustainable Materials and Design, sponsored by Siemens EnergyAlia Wahban, Hamilton, Ontario, Canada
Engineering Technology: Statics and Dynamics, sponsored by Howmet Aerospace FoundationChiyo Nakatsuji, Bunkyoku, Tokyo, Japan; Kevin Shen, Olympia, Washington
Environmental Engineering, sponsored by JacobsKrish Pai, San Diego, California; Jack Shannon, Clane, Kildare, Ireland
Materials Science, sponsored by Howmet Aerospace FoundationGrace Sun, Lexington, Kentucky
Mathematics, sponsored by Akamai FoundationAnna Oliva, Houston, Texas
Microbiology, sponsored by Schattner FoundationMatthew Chang, Irvine, California
Physics and Astronomy, sponsored by Richard F. Caris Charitable Trust IIHarini Thiagarajan and Vishal Ranganath Yalla, Bothell, Washington; Shuhan Luo, Worcester, Massachusetts
Plant Sciences, sponsored by Society for SciencePauline Estrada, Fresno, California; Tanishka Balaji Aglave, Dover, Florida
Robotics and Intelligent Machines, sponsored by RegeneronMichal Lajciak, Dubnica nad Vahom, Trenciansky kraj, Slovakia; Anthony Efthimiadis, Oakville, Ontario, Canada
Systems Software, sponsored by MicrosoftMichelle Wei, San Jose, California
Technology Enhances the Arts, sponsored by Society for ScienceAnant Khandelwal, Sritan Motati and Siddhant Sood, Alexandria, Virginia
Translational Medical Science, sponsored by RegeneronZheng-Chi Lee, West Lafayette, Indiana; Ingrid Wai Hin Chan, Hong Kong, China
The full list of all award-winning ISEF 2024 finalists is available here: https://www.societyforscience.org/press-release/regeneron-isef-2024-full-awards.
View all the finalists’ research here: https://projectboard.world/isef.
About the Regeneron International Science and Engineering FairThe Regeneron International Science and Engineering Fair (Regeneron ISEF), a program of Society for Science for over 70 years, is the world’s largest global science competition for high school students. Through a global network of local, regional and national science fairs, millions of students are encouraged to explore their passion for scientific inquiry. Each spring, a group of these students is selected as finalists and offered the opportunity to compete for approximately U.S. $9 million in awards and scholarships.
In 2019, Regeneron became the title sponsor of ISEF to help reward and celebrate the best and brightest young minds globally and encourage them to pursue careers in STEM to positively impact the world. Regeneron ISEF is supported by a community of additional sponsors, including Akamai Foundation, Alfred E. Mann Charities, Aramco, Caltech, Google.org, Gordon and Betty Moore Foundation, Howmet Aerospace Foundation, HP, , Jacobs, King Abdulaziz & his Companions Foundation for Giftedness and Creativity, Microsoft, National Geographic Society, Richard F. Caris Charitable Trust II, Rise, an initiative of Schmidt Futures and the Rhodes Trust, Schattner Foundation, Siemens Energy, Annenburg Foundation, Ballmer Group, Broadcom Foundation, Cesco Linguistic Services, Conrad N. Hilton Foundation, Edison International, Insaco, Oracle Academy, The Eli and Edythe Broad Foundation, The Ralph M. Parsons Foundation and US Army ROTC. Many are entrepreneurs across a wide range of industries. Learn more at https://www.societyforscience.org/isef/.
About Society for ScienceSociety for Science is a champion for science, dedicated to promoting the understanding and appreciation of science and the vital role it plays in human advancement. Established in 1921, Society for Science is best known for its award-winning journalism through Science News and Science News Explores, its world-class science research competitions for students, including the Regeneron Science Talent Search, the Regeneron International Science and Engineering Fair and the Thermo Fisher Scientific Junior Innovators Challenge, and its outreach and equity programming that seeks to ensure that all students have an opportunity to pursue a career in STEM. A 501(c)(3) membership organization, Society for Science is committed to inform, educate and inspire. Learn more at www.societyforscience.org and follow us on Facebook, Twitter, Instagram and Snapchat (Society4Science).
About RegeneronRegeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases and rare diseases. 
Regeneron believes that operating as a good corporate citizen is crucial to delivering on our mission. We approach corporate responsibility with three goals in mind: to improve the lives of people with serious diseases, to foster a culture of integrity and excellence and to build sustainable communities. Regeneron is proud to be included on the Dow Jones Sustainability World Index and the Civic 50 list of the most “community-minded” companies in the U.S. Throughout the year, Regeneron empowers and supports employees to give back through our volunteering, pro bono and matching gift programs. Our most significant philanthropic commitments are in the area of early science education, including the Regeneron Science Talent Search and the Regeneron International Science and Engineering Fair (ISEF).
For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.
More information about the top winners and access to visual assets visit:  https://www.societyforscience.org/isef-2024-media-kit.
Media ContactsJoseph Brown, [email protected]
Gayle Kansagor, Society for [email protected]
Photo – https://mma.prnewswire.com/media/2416174/Regeneron_ISEF_2024_Winners_Photo.jpg 
Logo – https://mma.prnewswire.com/media/2416197/Society_for_Science_Logo.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/more-than-9-million-awarded-to-high-school-scientists-and-engineers-at-the-regeneron-international-science-and-engineering-fair-2024-302149316.html

Continue Reading

Trending